Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dalbavancin For The Treatment Of Gram Positive Osteomyelitis Or Joint Infections Including Prosthetic Hip Or Knee Infections

NCT03426761 is registered in ClinicalTrials.gov with Infectious Diseases Physicians, Inc. as lead sponsor.

NCT NCT03426761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03426761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dalbavancin For The Treatment Of Gram Positive Osteomyelitis Or Joint Infections Including Prosthetic Hip Or Knee Infections
Lead sponsor
Infectious Diseases Physicians, Inc.
Phase
Phase 4
Overall status
Completed
Start date
January 25, 2018
Completion date
December 31, 2022
Enrollment
41 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bone infection, joint infection, osteomyelitis, prosthetic joint infection, septic arthritis